Martina Molsbergen

Ms.Molsbergen has +35 years of business development, marketing, and entrepreneurial experience including 26 years of business development experience in biotherapeutics and antibodies.  She has proven corporate development strategy and leadership experience within large and small company settings.  She is the CEO of C14 Consulting Group, a premier provider of strategic business strategy and licensing and deal negotiation. She was the Vice President of Business Development (PER. C6 Licensing) at Crucell Holland BV.  In this capacity she has established the PER.C6 manufacturing technology platform for therapeutic antibodies and proteins, manages global business development team as well as the joint venture with DSM Biologics.  She has brought more than twenty new licensing opportunities.

Previously as the Vice President of Business Development, Ms. Molsbergen played a key role in establishing and building BioWa, Inc., a novel antibody engineering platform company as a subsidiary of a Japanese company Kyowa Hakko Kogyo (KHK).  In three years of business activity, she successfully negotiated more than 15 deals valued at over $2.5 B in future milestone payments and royalties with leading antibody and biopharma companies.  She participated with KHK to identify new investment opportunities, and strategic planning for internal product pipeline development.  The efforts led to the creation of market value of BioWa to reach over $1B in three years. Ms.Molsbergen received two President’s awards for her achievements.  She has been featured in Nikkei Magazine for her business deal achievements with and on behalf of Japanese companies (May2007, June 2012).

In addition, Ms. Molsbergen has 12+ years of business development experience in small molecule pharmaceutical and manufacturing companies including Patheon, Watson Pharmaceuticals and FMC Corporation. She has a B.S. in Chemical Engineering from Drexel University.